Valneva's Phase 3 Data For Its Single-Shot Chikungunya Vaccine Candidate, VLA1553, Have Been Published In The Lancet, Showing VLA1553 Demonstrated A Seroresponse Rate Of 98.9%, And 96% Of Participants Maintained Seroresponse Six Months After Vaccination
Portfolio Pulse from Benzinga Newsdesk
Valneva has published Phase 3 data for its single-shot Chikungunya vaccine candidate, VLA1553, in The Lancet. The vaccine demonstrated a 98.9% seroresponse rate, with 96% of participants maintaining seroresponse six months after vaccination.
June 13, 2023 | 8:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Valneva's VLA1553 Chikungunya vaccine candidate shows promising Phase 3 results, with a 98.9% seroresponse rate and 96% maintaining seroresponse after six months.
The positive Phase 3 data for Valneva's Chikungunya vaccine candidate, VLA1553, indicates a high efficacy rate. This is likely to boost investor confidence in the company and its product pipeline, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100